6 DCAL share price target reports by brokerages below. See what is analyst's view on DCAL share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
Dishman Carbogen Amcis’ or DCAL’s 3QFY20 revenue at Rs5,423mn is 2.2% below our and 4.4% above consensus estimate. The Company had an EBITDA of Rs1,254 ( lower by 5.6% QoQ) and below our/consensus estimates by 22.4%/15.4%, respectively. Net profit at Rs329mn is below our/consensus estimate by 39.6%/37.1%, respectively. The margins were subdued in this quarter due to a higher proportion of CRAMS revenue coming from international operations. The gross margins were lower around 800bps QoQ, but for the full year it is expected to be in the range of 79-81%. In addition to higher cost of sales, employee expenses increased 10% QoQ as during the quarter, the company recorded annual bonus pay outs.
We have rolled over our valuation and shift from EV/EBITDA based valuation methodology to P/E based. We have adjusted our EPS for IND AS 116 Impact and have lowered our growth estimates for CRAMs business. We assign a 10x PE multiple to September 2021 earnings to arrive at a target price of Rs185 (from Rs369 earlier).
We remain constructive on DCAL owing to strong visibility on its order book, 15+ late phase 3 molecules, expanded development capacity, ability to work on new molecules like ADCs, and favorable currency. Improvement in BS driven by reduced debt and working capital release would be one of the important parameters to drive re-rating of the stock. At CMP, the stock is trading at 10.1/7.8 FY19/20E, a ~60% discount to peers like Divi’s Labs. Maintain BUY with a TP of Rs 350 (15x FY21E EPS).
We maintain a BUY on DCAL following a disappointing quarter. Our TP is revised to Rs 355 (15x FY21E EPS) with a 5% cut to FY21E EPS (higher depreciation expectation).
Despite a weak quarter, the company has maintained its full year guidance of 10% growth in revenue and EBITDA margin in the range of 26%-27%. Our forecasts assume revenue and EBITDA margin slightly above the guidance range. However, considering the market conditions, we lower our target valuation multiple on DCAL to 9x EV/EBITDA from 11x EV/EBITDA and arrive at a target price (TP) of Rs344.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.